Panobinostat

• Description:

  Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

• Product Name Alternative:

  LBH589; NVP-LBH589

• UNSPSC:

  12352005

• Hazard Statement:

  H301+H331, H315, H318, H360, H373

• Target:

  Apoptosis; Autophagy; HDAC; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Panobinostat.html

• Purity:

  99.37

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(/C=C/C1=CC=C(CNCCC2=C(NC3=C2C=CC=C3)C)C=C1)NO

• Molecular Formula:

  C21H23N3O2

• Molecular Weight:

  349.43

• Precautions:

  H301+H331, H315, H318, H360, H373

• References & Citations:

  [1]Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111 (10) :5093-100.|[2]Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8 (8) :2221-31.|[3]Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95 (5) :794-803.|[4]Barton K, et al. Broad activation of latent HIV-1 in vivo. Nat Commun. 2016;7:12731. Published 2016 Sep 8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  HDAC; HIV-1

• Citation 01:

  Acta Pharmacol Sin. 2021 May;42 (5) :814-823.|Anal Chem. 2025 Sep 2;97 (34) :18490-18498.|Arch Insect Biochem Physiol. 2021 Jul;107 (3) :e21823.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2022 Nov:155:113843.|Biomedicines. 2021 Dec 10;9 (12) :1873.|bioRxiv. 2019 Nov.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Jun 5.|bioRxiv. 2025 January 15.|BMC Pharmacol Toxicol. 2023 Sep 22;24 (1) :45.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Cancer Lett. 2021 Oct 10:518:180-195.|Cancer Lett. 2025 Sep 2:218001.|Cancer Res Commun. 2023 Aug 17;3 (8) :1580-1593.|Cancer Res Commun. 2025 Jun 1;5 (6) :1034-1048.|Cancer Res. 2016 Dec 1;76 (23) :7001-7011.|Cancer Res. 2023 Mar 2;83 (5) :686-699.|Cancer Res. 2025 Jun 2;85 (11) :2100-2116.|Cell Biol Int. 2021 May;45 (5) :1111-1121.|Cell Death Dis. 2022 Aug 17;13 (8) :717.|Cell Death Dis. 2024 Sep 11;15 (9) :665.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2024 May 24;43 (6) :114272.|Cells. 2020 Jul 10;9 (7) :1661.|China Biotechnology. 2016, 36 (6) : 9-17.|Clin Cancer Res. 2024 Nov 15;30 (22) :5166-5179.|Commun Biol. 2021 Oct 29;4 (1) :1235.|Departamento de Biotecnología. 2020 Sep.|Drug Des Devel Ther. 2018 Apr 30:12:1009-1017.|Eur J Pharmacol. 2020 May 15;875:173050.|Front Immunol. 2021 Aug 31;12:701671.|Gene. 2022 Jan 15:808:145977.|Hemasphere. 2024 Sep 26;8 (9) :e70006.|Hum Cell. 2023 Jan;36 (1) :366-376.|Insect Mol Biol. 2020 Feb;29 (1) :104-111.|Insects. 2023 Mar 23;14 (4) :309.|Int Immunopharmacol. 2025 Oct 10:167:115637.|Int J Biochem Cell Biol. 2020 May;122:105734.|Int J Mol Sci. 2024 Nov 9;25 (22) :12035.|Int J Oncol. 2020 Jun;56 (6) :1429-1441.|J Appl Toxicol. 2023 Aug;43 (8) :1214-1224.|J Clin Endocrinol Metab. 2021 Jan 1;106 (1) :e232-e246.|J Drug Deliv Sci Technol. 2025 Nov:113:107341.|J Exp Clin Cancer Res. 2022 Nov 11;41 (1) :321.|J Med Chem. 2024 Sep 12;67 (17) :15098-15117.|J Med Chem. 2025 Oct 17.|J Nanobiotechnology. 2024 Dec 16;22 (1) :753.|J Recept Signal Transduct Res. 2022 Feb;42 (1) :100-108.|J Virol. 2021 Sep 9;95 (19) :e0022721.|JCI Insight. 2025 Oct 9:e195385.|Leukemia. 2023 Jun;37 (6) :1336-1348.|Mol Immunol. 2023 Dec:164:98-111.|Nat Commun. 2023 Apr 13;14 (1) :2095.|Nat Commun. 2024 Jul 2;15 (1) :5570.|Neurooncol Adv. 2021 Jul 17;3 (1) :vdab099.|Neuroscience. 2021 Jun 15:465:38-45.|NPJ Breast Cancer. 2023 Aug 11;9 (1) :66.|Patent. US20180263995A1.|Patent. US20240344035A1|Patent. US20240344035A1.|Patent. US20250152731A1.|Pharmaceuticals (Basel) . 2021 Nov 30;14 (12) :1244.|PLoS One. 2022 Feb 14;17 (2) :e0263822.|PLoS Pathog. 2018 Sep 13;14 (9) :e1007267. |Proteome Sci. 2024 May 15;22 (1) :6.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 Aug 14.|Rheumatology (Oxford) . 2025 Aug 13:keaf437.|Sci Transl Med. 2022 Aug 10;14 (657) :eabg3277.|Signal Transduct Target Ther. 2025 Oct 14;10 (1) :341.|SSRN. 2023 Sep 29.|The Faculty For Chemie And Pharmazie, Albert-ludwigs-university Of Freiburg. 2019 Dec.|The Ohio State University. 2024 May.|University of Gothenburg. 2023 Jun 27.|Uppsala University. 2025.|Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.|Patent. US20250161243A1.

• CAS Number:

  [404950-80-7]